v3.22.2.2
Stockholders' Equity (Deficit) (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders Equity Note [Abstract]  
Schedule of exercisable outstanding warrants for purchase of common stock issued

At September 30, 2022, the Company had the following exercisable outstanding warrants for the purchase of common stock issued in connection with the Company’s loan agreements with SVB:

 

Expiration

 

Number of shares

 

 

Exercise price

November 14, 2023 through June 4, 2024

 

 

3,874

 

 

$

77.40

 

January 25, 2024

 

 

4,669

 

 

$

51.40

 

May 3, 2025

 

 

5,363

 

 

$

26.10

 

 

 

 

13,906

 

 

 

 

 

As of September 30, 2022, the Company had the following outstanding warrants for the purchase of common stock:

 

Expiration

 

Number of shares

 

 

Exercise price

 

November 14, 2023 through June 4, 2024

 

 

3,874

 

 

$

77.40

 

January 25, 2024

 

 

4,669

 

 

$

51.40

 

March 27, 2024

 

 

1,369,602

 

 

$

27.00

 

May 3, 2025

 

 

5,363

 

 

$

26.10

 

August 27, 2030

 

 

1,889,513

 

 

$

0.01

 

August 31, 2030

 

 

1,358,993

 

 

$

0.01

 

June 21, 2032

 

 

2,205,018

 

 

$

0.01

 

September 2, 2032

 

 

150,753

 

 

$

1.99

 

 

 

 

6,987,785

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary of weighted-average assumptions used Black-Scholes option pricing model to determine the fair value

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

 

 

September 30,

 

 

September 30,

 

 

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

Risk-free interest rate

 

 

 

 

 

0.9

%

 

 

1.9

%

 

 

0.8

%

 

 

Expected volatility

 

 

 

 

 

89

%

 

 

90

%

 

 

90

%

 

 

Expected term (in years)

 

 

 

 

 

6.3

 

 

 

6.2

 

 

 

6.2

 

 

 

Expected dividend yield

 

 

%

 

 

%

 

 

%

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary of allocation of stock-based compensation expense

The allocation of stock-based compensation expense was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

 

September 30,

 

 

September 30,

 

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

Research and development

 

$

211

 

 

$

176

 

 

 

$

620

 

 

 

$

447

 

 

General and administrative

 

 

270

 

 

 

325

 

 

 

 

944

 

 

 

 

814

 

 

 

 

$

481

 

 

$

501

 

 

 

$

1,564

 

 

 

$

1,261